GT
BMY.RT

Glenview Trust’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Glenview Trust’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,615
Closed -$38K – 350
2019
Q4 		$38K Buy
+12,615
New +$32.8K ﹤0.01% 343

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Glenview Trust's BMY.RT Position: Q1 2020 in Review

Glenview Trust sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2020, closing a stake of 12,615 shares — an estimated $38K sold.

Glenview Trust first reported a position in BMY.RT in Q4 2019 and held it in 1 quarter. The position peaked at $38K in Q4 2019. 581 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2020.

  • Glenview Trust reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
  • Glenview Trust sold 12,615 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2020, an estimated $38K.
  • Glenview Trust first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 1 quarter.
  • Glenview Trust's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $38K in Q4 2019.
  • 581 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2020.

Based on Glenview Trust's 13F filing for Q1 2020, filed 28 Apr 2020.